R44HL129577
Project Grant
Overview
Grant Description
Development of a polymeric percutaneous pulmonary valve for use in young children - Project Summary:
Congenital heart disease (CHD) remains the most common category of birth defect and a leading cause of childhood death in the developed world. Of the constellation of structural defects that comprise CHD, dysfunctional pulmonary valves (PV) are a common abnormality, and frequently require surgical intervention and replacement.
Valve replacement through open heart surgery carries substantial risk and discomfort for patients, and represents a major financial and emotional burden for families. The most commonly used valves for pulmonary valve replacement in young children are biologically-derived (e.g. human cadaveric valves). Such replacements are in short supply, and have other inherent disadvantages, such as poor long-term durability, and propensity to induce a host immune response.
The combination of these factors leads to a cycle of repeat surgical interventions, using valves that are scarcely available and destined for rapid failure. Polyvascular has sought to address these issues by developing a polymeric stent-mounted valve (SMV), comprised of polymer-derived leaflets mounted within a metal stent, that can be delivered via minimally invasive transcatheter techniques, avoiding the burden of repeat surgeries, with potential for improved durability and function.
The present supplement is meant to support Kelly McKinzey’s training in medical device development with Polyvascular in preparation for an independent career leading health-related research and development for small businesses, under PA-18-837. The proposal consists of two training components:
In the research plan, Ms. McKinzey will employ alternate methods for leaflet fabrication, and test these against Polyvascular’s standard methods. She will gain training in stent mounted valve manufacturing, polymer chemistry, ISO 5840-3 benchtop testing, ISO 10993 biocompatibility testing, sterilization validation, and packaging validation. All steps will be conducted under a quality system, and Ms. McKinzey will gain experience in adhering to this system.
A second training component involves her career and mentorship plan, in which she will take advantage of the startup ecosystem in the Texas Medical Center, through courses at Enventure and other local institutions. She will gain experience in entrepreneurship and responsible conduct of research, within the framework of device development for FDA approval.
Both elements of the proposal are intended to surround Ms. McKinzey with an interdisciplinary team of experienced researchers, and ready her for a career in medical device development.
Congenital heart disease (CHD) remains the most common category of birth defect and a leading cause of childhood death in the developed world. Of the constellation of structural defects that comprise CHD, dysfunctional pulmonary valves (PV) are a common abnormality, and frequently require surgical intervention and replacement.
Valve replacement through open heart surgery carries substantial risk and discomfort for patients, and represents a major financial and emotional burden for families. The most commonly used valves for pulmonary valve replacement in young children are biologically-derived (e.g. human cadaveric valves). Such replacements are in short supply, and have other inherent disadvantages, such as poor long-term durability, and propensity to induce a host immune response.
The combination of these factors leads to a cycle of repeat surgical interventions, using valves that are scarcely available and destined for rapid failure. Polyvascular has sought to address these issues by developing a polymeric stent-mounted valve (SMV), comprised of polymer-derived leaflets mounted within a metal stent, that can be delivered via minimally invasive transcatheter techniques, avoiding the burden of repeat surgeries, with potential for improved durability and function.
The present supplement is meant to support Kelly McKinzey’s training in medical device development with Polyvascular in preparation for an independent career leading health-related research and development for small businesses, under PA-18-837. The proposal consists of two training components:
In the research plan, Ms. McKinzey will employ alternate methods for leaflet fabrication, and test these against Polyvascular’s standard methods. She will gain training in stent mounted valve manufacturing, polymer chemistry, ISO 5840-3 benchtop testing, ISO 10993 biocompatibility testing, sterilization validation, and packaging validation. All steps will be conducted under a quality system, and Ms. McKinzey will gain experience in adhering to this system.
A second training component involves her career and mentorship plan, in which she will take advantage of the startup ecosystem in the Texas Medical Center, through courses at Enventure and other local institutions. She will gain experience in entrepreneurship and responsible conduct of research, within the framework of device development for FDA approval.
Both elements of the proposal are intended to surround Ms. McKinzey with an interdisciplinary team of experienced researchers, and ready her for a career in medical device development.
Awardee
Funding Goals
TO FOSTER HEART AND VASCULAR RESEARCH IN THE BASIC, TRANSLATIONAL, CLINICAL AND POPULATION SCIENCES, AND TO FOSTER TRAINING TO BUILD TALENTED YOUNG INVESTIGATORS IN THESE AREAS, FUNDED THROUGH COMPETITIVE RESEARCH TRAINING GRANTS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Texas
United States
Geographic Scope
State-Wide
Analysis Notes
Amendment Since initial award the End Date has been extended from 12/31/22 to 02/29/28 and the total obligations have increased 221% from $1,007,115 to $3,231,750.
Polyvascular was awarded
Percutaneous Polymeric Pulmonary Valve for Pediatric Heart Health
Project Grant R44HL129577
worth $3,231,750
from National Heart Lung and Blood Institute in August 2016 with work to be completed primarily in Texas United States.
The grant
has a duration of 11 years 6 months and
was awarded through assistance program 93.837 Cardiovascular Diseases Research.
The Project Grant was awarded through grant opportunity NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional).
SBIR Details
Research Type
SBIR Phase II
Title
Development of a Polymeric Percutaneous Pulmonary Valve for Use in Young Children
Abstract
Project Summary: Congenital heart disease (CHD) remains the most common category of birth defect and a leading cause of childhood death in the developed world. Of the constellation of structural defects that comprise CHD, dysfunctional pulmonary valves (PV) are a common abnormality, and frequently require surgical intervention and replacement. Valve replacement through open heart surgery carries substantial risk and discomfort for patients, and represents a major financial and emotional burden for families. The most commonly used valves for pulmonary valve replacement in young children are biologically-derived (e.g. human cadaveric valves). Such replacements are in short supply, and have other inherent disadvantages, such as poor long-term durability, and propensity to induce a host immune response. The combination of these factors leads to a cycle of repeat surgical interventions, using valves that are scarcely available and destined for rapid failure. PolyVascular has sought to address these issues by developing a polymeric stent-mounted valve (SMV), comprised of polymer-derived leaflets mounted within a metal stent, that can be delivered via minimally invasive transcatheter techniques, avoiding the burden of repeat surgeries, with potential for improved durability and function. The present supplement is meant to support Kelly McKinzey’s training in medical device development with PolyVascular in preparation for an independent career leading health-related research and development for small businesses, under PA-18-837. The proposal consists of two training components: in the Research Plan, Ms. McKinzey will employ alternate methods for leaflet fabrication, and test these against PolyVascular’s standard methods. She will gain training in stent mounted valve manufacturing, polymer chemistry, ISO 5840-3 benchtop testing, ISO 10993 biocompatibility testing, sterilization validation, and packaging validation. All steps will be conducted under a quality system, and Ms. McKinzey will gain experience in adhering to this system. A second training component involves her Career and Mentorship Plan, in which she will take advantage of the startup ecosystem in the Texas Medical Center, through courses at Enventure and other local institutions. She will gain experience in entrepreneurship and responsible conduct of research, within the framework of device development for FDA approval. Both elements of the proposal are intended to surround Ms. McKinzey with an interdisciplinary team of experienced researchers, and ready her for a career in medical device development.Project Summary: Patients born with congenital heart defects often require replacement of their pulmonary valve, which allows the heart to pump to the lungs. Conventionally, such valve replacements require open-heart surgery, which carries significant risk and discomfort. Our proposal describes the development of a new heart valve platform, across a range of sizes for small children, adolescents, and adults, which can be delivered in a minimally-invasive fashion through the groin without open-heart surgery.
Topic Code
NHLBI
Solicitation Number
PA18-837
Status
(Ongoing)
Last Modified 3/5/25
Period of Performance
8/15/16
Start Date
2/29/28
End Date
Funding Split
$3.2M
Federal Obligation
$0.0
Non-Federal Obligation
$3.2M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R44HL129577
Transaction History
Modifications to R44HL129577
Additional Detail
Award ID FAIN
R44HL129577
SAI Number
R44HL129577-2807407663
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Small Business
Awarding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Funding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Awardee UEI
TKP8JARF2KH9
Awardee CAGE
767J9
Performance District
TX-90
Senators
John Cornyn
Ted Cruz
Ted Cruz
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Heart, Lung, and Blood Institute, National Institutes of Health, Health and Human Services (075-0872) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,231,821 | 100% |
Modified: 3/5/25